Post-earnings recap
Reported
Thu, Mar 4, 2010
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a 9.03% decline in stock price following the announcement. The lack of revenue figures and forward guidance adds uncertainty for investors. The focus remains on their clinical trials, but the financial results may raise concerns about their short-term performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | -49.83% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to advancing their pipeline despite the current financial results.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials and product development.